SCHEMBL30003517

SCHEMBL30003517

Cc1cc(C(=O)CCc2sc(-c3ccc(C(F)(F)F)cc3)cc2C(C)C)ccc1OC(C)(C)CO

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 19/20 0.37
PPARA Q07869 15/20 0.37
PPARG P37231 9/20 0.37
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24656252 1.00 PPARD (0.37) PPARDPPARAPPARGMAPT
SCHEMBL1765881 0.90 PPARA (0.47) PPARDPPARAPPARG
SCHEMBL30003690 0.88 PPARD (0.40) PPARDPPARAPPARG
SCHEMBL24656247 0.88 PPARD (0.40) PPARDPPARAPPARG
SCHEMBL4101642 0.88 PPARD (0.39) PPARDPPARAPPARGMAPT
SCHEMBL1765904 0.85 PPARD (0.51) PPARDPPARAPPARG
SCHEMBL4097006 0.84 HSD17B1 (0.35) PPARDPPARAPPARGMAPT
SCHEMBL24742581 0.83 PPARD (0.54) PPARDPPARAPPARGMAPT
SCHEMBL30002969 0.83 PPARD (0.54) PPARDPPARAPPARGMAPT
SCHEMBL12732559 0.83 CTNNB1 (0.37) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333379-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2025-10-30 US disclosed
US-12297168-B2 Compounds useful for treating liver diseases ABIONYX PHARMA SA (FR) 2025-05-13 US disclosed
US-20240199575-A1 COMPOUNDS USEFUL FOR TREATING LIVER DISEASES ABIONYX PHARMA SA (FR) 2024-06-20 US disclosed
US-20230278952-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2023-09-07 US disclosed
US-11634387-B2 Compounds useful for treating liver diseases ABIONYX PHARMA SA (FR) 2023-04-25 US disclosed
US-20220363632-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2022-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278952-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-20240199575-A1 COMPOUNDS USEFUL FOR TREATING LIVER DISEASES SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-11634387-B2 Compounds useful for treating liver diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-20250333379-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-12297168-B2 Compounds useful for treating liver diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-20220363632-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.